Dr. Anita Tipirneni, MD

Dr. Tipirneni practices at Regents of the University of California Los Angeles in Porter Ranch, California.

Dr. Tipirneni's NPI, 1588923064, was assigned on May 3, 2012. Dr. Tipirneni graduated from Jacobs School of Medicine and Biomedical Sciences in 2012. Dr. Tipirneni holds California license A143038.

Dr. Tipirneni's primary practice is Regents of the University of California Los Angeles, at 19950 W Rinaldi St, Porter Ranch, CA 91326 in Los Angeles County. The practice phone is (310) 391-7281.

Dr. Tipirneni's primary practice is Regents of the University of California Los Angeles in Porter Ranch, California. Dr. Tipirneni is also affiliated with Ronald Reagan UCLA Medical Center. The medical group on file is UCLA Neurology. Dmand AI also links Dr. Tipirneni to 1 more hospital, 2 group practices and clinics, 1 home health agency and 1 medical group, each named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Tipirneni practices, 5 sites in all. Vendor and product names are available with a free account.

Neurology is Dr. Tipirneni's primary specialty in the NPI Registry, under taxonomy code 2084N0400X. Dr. Tipirneni is board certified in neurology by the American Board of Psychiatry and Neurology. Dr. Tipirneni is licensed in California.

Dmand AI lists acute mini-stroke (TIA), alzheimer's disease, carpal tunnel syndrome, cerebrovascular disease, epilepsy, essential tremor, fibromyalgia and chronic pain and lower back pain among the conditions Dr. Tipirneni treats.

CMS data shows 689 Medicare services from Dr. Tipirneni across 9 procedure codes in 2024, for 382 Medicare patients. Medicare paid $72,969 for them.

CMS counts 382 Medicare patients who saw Dr. Tipirneni in 2024. The largest group is 65 to 74, with 153 patients. 75% of them have high blood pressure, and 75% have high cholesterol. 36% are also on Medicaid. Their average risk score is 2.15, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dr. Tipirneni's median patient age at 64, with 60% women.

In 2024, Dr. Tipirneni wrote 778 Medicare Part D claims for 207 patients. 85% of them were for generic drugs. CMS names the drug for 574 of them, across 22 drugs with 11 or more claims each, at $115,582 in total drug cost. In 2023, CMS named 855 claims across 26 drugs.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 87 out of 100 for Dr. Tipirneni for performance year 2024, reported as part of a group. Dr. Tipirneni accepts Medicare assignment, so Medicare's approved amount is taken as full payment. CMS lists Dr. Tipirneni as offering telehealth.

Dmand AI links 13 papers to Dr. Tipirneni, published from 2012 to 2017. 2016 was the busiest year, with 5. The most frequent topics are Magnetic Resonance Imaging. Dr. Tipirneni has published most often in Intern Emerg Med. Dr. Tipirneni's most frequent co-authors are Dileep Rajhavendra Yavagal, MD, Kunakorn Charmin Atchaneeyasakul and Priyank Khandelwal, MD.

CMS Open Payments shows 300 general payments to Dr. Tipirneni from 26 drug and device companies from 2016 to 2025. Food and beverage make up the largest share, 99% of the total. Teva Pharmaceuticals USA, Inc. paid the most, $1,621.

Dr. Tipirneni graduated from Jacobs School of Medicine and Biomedical Sciences in 2012.

Dr. Tipirneni is in network with 14 carriers, including Aetna, Blue Cross Blue Shield of Michigan and United Healthcare. PPO plans come from the most carriers, 9. Check the plan with the practice before a visit.